Alendronate treatment for osteoporosis: a review of the clinical evidence.
Bisphosphonates have recently gained an increasing role in the management of osteoporosis. The aminobisphosphonate, alendronate has recently been introduced as a new agent for the treatment of postmenopausal osteoporosis. This paper reviews the clinical evidence for the use of this agent and seeks to assess its place in osteoporosis management.
Selby
P
P
University of Manchester Department of Medicine, UK. Peter.Selby@man.ac.uk
D019386:Alendronate / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050723:Fractures, Bone / Q000209:etiology / Q000378:metabolism / Q000517:prevention & control; D006801:Humans; D010024:Osteoporosis / Q000150:complications / Q000188:drug therapy* / Q000378:metabolism; D012449:Safety; D016896:Treatment Outcome
D019386:Alendronate